Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire • Monday
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 11/02/26
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026GlobeNewsWire • 10/23/26
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractGlobeNewsWire • 10/18/26
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of AzenosertibSeeking Alpha • 08/31/26
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 08/17/26
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire • 08/06/26
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026GlobeNewsWire • 07/17/26
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial StrategyGlobeNewsWire • 05/27/26
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026GlobeNewsWire • 05/21/26
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical ProgressGlobeNewsWire • 05/12/26
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian CancerGlobeNewsWire • 05/05/26
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/01/26
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian CancerGlobeNewsWire • 04/21/26
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026GlobeNewsWire • 04/17/26
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian CancerGlobeNewsWire • 04/09/26
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational UpdatesGlobeNewsWire • 03/26/26
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewsWire • 03/17/26